Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Metastatic Breast Cancer With Active Brain Metastasis Clear all

Completed Phase 1 Interventional Results available

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

NCT01770353

View directory record Official record

Conditions: Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
Interventions: Ferumoxytol, MM-398; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older

Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 7
States / cities: Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more

Source: ClinicalTrials.gov public record

Updated Nov 26, 2019 · Synced May 21, 2026, 5:35 PM EDT

Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

NCT04538742

View directory record Official record

Conditions: Metastatic Breast Cancer
Interventions: Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Pertuzumab, Tucatinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older

Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 10
States / cities: Fort Myers, Florida • St. Petersburg, Florida • Commack, New York + 6 more

Source: ClinicalTrials.gov public record

Updated Dec 7, 2025 · Synced May 21, 2026, 5:35 PM EDT

Recruiting Phase 2 Interventional

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

NCT04965064

View directory record Official record

Conditions: Breast Cancer
Interventions: Capecitabine and Neratinib.; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older

Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Source: ClinicalTrials.gov public record

Updated Dec 14, 2025 · Synced May 21, 2026, 5:35 PM EDT

Completed Phase 1 Interventional

Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study

NCT04456140

View directory record Official record

Conditions: Breast Carcinoma, Digestive System Neoplasm, Malignant Brain Neoplasm, Malignant Central Nervous System Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Genitourinary System Neoplasm, Malignant Head and Neck Neoplasm, Malignant Musculoskeletal Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm of Unknown Primary, Skin Carcinoma
Interventions: Biospecimen Collection, Genetic Counseling, Genetic Testing, Survey Administration; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older

Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Scottsdale, Arizona • Jacksonville, Florida

Source: ClinicalTrials.gov public record

Updated Jul 23, 2023 · Synced May 21, 2026, 5:35 PM EDT

Recruiting Phase 1Phase 2 Interventional

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

NCT06907043

View directory record Official record

Conditions: Advanced Solid Tumors
Interventions: EIK1004-001 (IMP1707-001); Drug
Lead sponsor: Eikon Therapeutics; Industry
Eligibility: 18 Years to 89 Years

Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Denver, Colorado • Lake Mary, Florida • Boston, Massachusetts + 3 more

Source: ClinicalTrials.gov public record

Updated Aug 18, 2025 · Synced May 21, 2026, 5:35 PM EDT

Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Sac-TMT for Active TNBC Brain Metastases

NCT07458113

View directory record Official record

Conditions: Metastatic Triple Negative Breast Cancers
Interventions: Sacituzumab tirumotecan; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older

Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Haven, Connecticut

Source: ClinicalTrials.gov public record

Updated Mar 8, 2026 · Synced May 21, 2026, 5:35 PM EDT